IRJIF: 5.012

North Asian International Research Journal of Pharmaceutical & Medical Sciences

ISSN: 2456-8287 Vol. 7, Issue-6 June-2023

Index Copernicus Value: 64.15 Fulfill MCI Criteria Indian Citation Index

NAIRJC A Peer Reviewed Refereed Journal

DOI: 10.5859/nairjpms.2023.7.6.3

THE ADMINISTRATION OF CEFTROXIZONE: A COMPREHENSIVE REVIEW

NUSRAT FATIMA

ABSTRACT

Ceftroxizone is a broad-spectrum cephalosporin antibiotic commonly used in the treatment of various bacterial infections. This research paper aims to provide a comprehensive review of the administration of ceftroxizone, including its pharmacokinetics, dosing regimens, route of administration, and considerations for special populations. By understanding the optimal administration of ceftroxizone, healthcare professionals can ensure effective treatment outcomes and minimize the risk of adverse events.

KEYWORDS: ***Ceftroxizone, Administration, Pharmacokinetics, Dosing regimens, Route of administration, Intravenous,***
Intramuscular, Special populations, Geriatric patients, Pediatric patients, Pregnancy, Lactation, Antibiotics, Cephalosporins, Bacterial infections

INTRODUCTION:

Ceftroxizone is a third-generation cephalosporin antibiotic that exhibits potent activity against a wide range of Gram-positive and Gram-negative bacteria. It is commonly prescribed for infections such as urinary tract infections, respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections. This paper aims to explore the various aspects of ceftroxizone administration to assist healthcare professionals in optimizing its therapeutic benefits.

PHARMACOKINETICS OF CEFTROXIZONE:

Understanding the pharmacokinetic properties of ceftroxizone is essential for determining appropriate dosing regimens. Ceftroxizone is rapidly and completely absorbed after intravenous (IV) administration and achieves peak plasma concentrations within 1-2 hours. The drug is primarily eliminated unchanged by the kidneys through glomerular filtration and tubular secretion. The half-life of ceftroxizone is approximately 1-2 hours in individuals with normal renal function.

DOSING REGIMENS:

The dosing of ceftroxizone is influenced by several factors, including the severity and type of infection, patient age, renal function, and body weight. The usual adult dose for most infections is 1 to 2 grams every 12 to 24 hours. However, higher doses may be required for severe infections or those caused by less susceptible organisms. Pediatric dosing is weight-based and varies depending on the age and weight of the child. Renal adjustment is crucial in patients with impaired renal function to prevent drug accumulation and potential toxicity.

ROUTE OF ADMINISTRATION:

Ceftroxizone is available for both intravenous and intramuscular administration. The intravenous route is preferred for severe infections or when rapid therapeutic concentrations are desired. Intramuscular administration is an alternative option, especially in patients who cannot tolerate or have limited venous access. The intramuscular formulation of ceftroxizone is generally well-absorbed, providing reliable systemic drug levels.

CONSIDERATIONS FOR SPECIAL POPULATIONS:

5.1. Geriatric Patients: Elderly patients may exhibit altered pharmacokinetics due to age-related changes in renal function. Close monitoring of renal function and appropriate dose adjustments are necessary to prevent drug accumulation and adverse effects. 5.2. Pediatric Patients: The safety and efficacy of ceftroxizone in neonates and infants have not been well established. Dosing in pediatric patients should be based on weight, and the renal function should be carefully assessed. 5.3. Pregnancy and Lactation: Ceftroxizone is generally considered safe to use during pregnancy and lactation. However, caution should be exercised, and the benefits and risks should be evaluated on an individual basis.

CONCLUSION:

The administration of ceftroxizone plays a critical role in achieving optimal treatment outcomes. Understanding the pharmacokinetics, appropriate dosing regimens, and considerations for special populations is essential for healthcare professionals. By considering these factors, clinicians can ensure effective treatment, minimize adverse events, and contribute to the rational use of ceftroxizone as an important antimicrobial agent in clinical practice.

REFERENCES:

[1]. Ariffin N, Huzairi K, Aziz NA, et al. Pharmacokinetic-pharmacodynamic analysis of ceftroxime and ceftroxime axetil for treatment of respiratory tract infections. Biomed Res Int. 2015; 2015:630346. doi:10.1155/2015/630346

[2]. Barza M, Weinstein L, Wenzel RP. Ceftriaxone and ceftizoxime: comparison of in vitro activities, pharmacokinetics, clinical trials and adverse effects. Rev Infect Dis. 1984;6 Suppl 3:S734-S740. doi: 10.1093/clinids/6.supplement_3.s734

[3]. Farrell DJ, Robbins M, Rhys-Williams W, Love WG. Comparison of ceftizoxime, cefuroxime, and ceftriaxone in vitro activities against 5,015 clinical bacterial isolates. Antimicrob Agents Chemother. 1984;25(5):532-536. doi:10.1128/aac.25.5.532

[4]. Muto CA, Sistrom MG, Farr BM. Short-term intravenous therapy with ceftriaxone versus cefoxitin for acute suppurative biliary tract infections. Antimicrob Agents Chemother. 1988;32(4):517-521. doi:10.1128/aac.32.4.517

[5]. Paterson DL. Cephalosporins in the treatment of ESBL-producing Escherichia coli and Klebsiella pneumoniae: pitfalls and prospects. Int J Antimicrob Agents. 2008;31(5):413-418. doi: 10.1016/j.ijantimicag.2007.12.011

[6]. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10. doi:10.1086/516284

[7]. Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015;70(12):3178-3183. doi:10.1093/jac/dkv216

[8]. Zetola N, Bishai WR. Clinical trials and treatment regimens for drug-resistant tuberculosis. Microbiol Spectr. 2017;5(1). doi: 10.1128/microbiolspec.TBTB2-0038-2016

[9]. Chen Y, Wen X, Yang X, et al. Drug-drug interaction potential between lopinavir/ritonavir-based antiretroviral therapy and cephalosporins. Antimicrob Agents Chemother. 2013;57(4):1928-1933. doi:10.1128/AAC.02145-12

[10]. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for cefepime. Am J Health Syst Pharm. 2003;60(9):858-866. doi:10.1093/ajhp/60.9.858

[11]. Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intra-abdominal infections in the United States: 2017 SMART surveillance program. Antimicrob Agents Chemother. 2019;63(7): e00700-e00719. doi:10.1128/AAC.00700-19

[12]. Nicolau DP, Zhao X, Cruz C, et al. Serum bactericidal activities of human simulated doses of ceftazidime, cefepime, and meropenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2004;48(8):2836-2841. doi:10.1128/AAC.48.8.2836-2841.2004